title: Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
abstract: Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit.
authors.affiliation: Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia 23298, USA. rakesh@vcu.edu
authors.forename: Rakesh C
authors.initials: RC
authors.lastname: Kukreja
authors.forename: Fadi N
authors.initials: FN
authors.lastname: Salloum
authors.forename: Anindita
authors.initials: A
authors.lastname: Das
mesh_terms: D000818:Animals; D006157:Guanosine Monophosphate / Q000378:metabolism*; D006331:Heart Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D006157:Guanosine Monophosphate